Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response

Kidney International

Volumn 85, Issue 2, 2014, Pages 333-343

  Jiang, Tao ^a,b   Tian, Fei ^c   Zheng, Hongting ^d   Whitman, Samantha A ^a   Lin, Yifeng ^b   Zhang, Zhigang ^b   Zhang, Nong ^b   Zhang, Donna D ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b FUDAN UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

iNOS; lupus nephritis; NF kB; Nrf2; ROS; TGFb1

Indexed keywords

FIBRONECTIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY R4A; MOPC 141 ANTIBODY; P65 INHIBITOR; PRISTANE; PROTEIN INHIBITOR; REACTIVE OXYGEN METABOLITE; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; SMALL INTERFERING RNA; SULFORAPHANE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE; GENETIC TRANSFECTION; GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MESANGIUM CELL; MORTALITY; MOUSE; NADPH GENE; NONHUMAN; NQO1 GENE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SPLEEN WEIGHT; UPREGULATION;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DNA DAMAGE; FEMALE; FIBRONECTINS; FULLERENES; HUMANS; INFLAMMATION MEDIATORS; ISOTHIOCYANATES; KIDNEY GLOMERULUS; LUPUS NEPHRITIS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; NF-E2-RELATED FACTOR 2; NF-KAPPA B; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84895910708     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.343     Document Type: Article

References (37)

1. Cameron JS. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-424
2. Couser WG. Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol 2012; 23: 381-399
3. Kaveri SV, Mouthon L, Bayry J. Basophils and nephritis in lupus. N Engl J Med 2010; 363: 1080-1082
4. Grande JP. Experimental models of lupus nephritis. Contrib Nephrol 2011; 169: 183-197
5. Kovacic P, Jacintho JD. Systemic lupus erythematosus and other autoimmune diseases from endogenous and exogenous agents: Unifying theme of oxidative stress. Mini Rev Med Chem 2003; 3: 568-575
6. Nath KA, Fischereder M, Hostetter TH. The role of oxidants in progressive renal injury. Kidney Int Suppl 1994; 45: S111-S115
7. Evans MD, Cooke MS, Akil M et al. Aberrant processing of oxidative DNA damage in systemic lupus erythematosus. Biochem Biophys Res Commun 2000; 273: 894-898
8. Frostegard J, Svenungsson E, Wu R et al. Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations. Arthritis Rheum 2005; 52: 192-200
9. Morgan PE, Sturgess AD, Hennessy A et al. Serum protein oxidation and apolipoprotein CIII levels in people with systemic lupus erythematosus with and without nephritis. Free Radic Res 2007; 41: 1301-1312
10. Grande JP. Mechanisms of progression of renal damage in lupus nephritis: Pathogenesis of renal scarring. Lupus 1998; 7: 604-610
11. Itoh K, Ishii T, Wakabayashi N et al. Regulatory mechanisms of cellular response to oxidative stress. Free Radic Res 1999; 31: 319-324
12. Kensler TW, Wakabayashi N, Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47: 89-116
13. Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 2006; 38: 769-789
14. Chan K, Han XD, Kan YW. An important function of Nrf2 in combating oxidative stress: Detoxification of acetaminophen. Proc Natl Acad Sci USA 2001; 98: 4611-4616
15. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 2004; 10: 549-557
16. Ahmad R, Raina D, Meyer C et al. Triterpenoid CDDO-Me blocks the NF-kappaB pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem 2006; 281: 35764-35769
17. Karuri AR, Huang Y, Bodreddigari S et al. 3H-1,2-dithiole-3-Thione targets nuclear factor kappaB to block expression of inducible nitric-oxide synthase, prevents hypotension, and improves survival in endotoxemic rats. J Pharmacol Exp Ther 2006; 317: 61-67
18. Sriram N, Kalayarasan S, Sudhandiran G. Epigallocatechin-3-gallate augments antioxidant activities and inhibits inflammation during bleomycin-induced experimental pulmonary fibrosis through Nrf2-Keap1 signaling. Pulm Pharmacol Ther 2009; 22: 221-236
19. Jiang T, Huang Z, Lin Y et al. The protective role of Nrf2 in streptozotocininduced diabetic nephropathy. Diabetes 2010; 59: 850-860
20. Zhang DD. The Nrf2-Keap1-ARE signaling pathway: The regulation and dual function of Nrf2 in cancer. Antioxid Redox Signal 2010; 13: 1623-1626
21. Hu R, Saw CL, Yu R et al. Regulation of Nrf2 signaling for cancer chemoprevention: Antioxidant coupled with anti-inflammatory. Antioxid Redox Signal 2010; 13: 1679-1698
22. Yoh K, Itoh K, Enomoto A et al. Nrf2-deficient female mice develop lupuslike autoimmune nephritis. Kidney Int 2001; 60: 1343-1353
23. Morito N, Yoh K, Hirayama A et al. Nrf2 deficiency improves autoimmune nephritis caused by the fas mutation lpr. Kidney Int 2004; 65: 1703-1713
24. Li J, Stein TD, Johnson JA. Genetic dissection of systemic autoimmune disease in Nrf2-deficient mice. Physiol Genomics 2004; 18: 261-272
25. Ma Q, Battelli L, Hubbs AF. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-Activated transcription factor Nrf2. Am J Pathol 2006; 168: 1960-1974
26. Moroni G, Novembrino C, Quaglini S et al. Oxidative stress and homocysteine metabolism in patients with lupus nephritis. Lupus 2010; 19: 65-72
27. Cordova E, Velazquez-Cruz R, Centeno F et al. The NRF2 gene variant-653G/A is associated with nephritis in childhood-onset systemic lupus erythematosus. Lupus 2010; 19: 1237-1242
28. Tsai PY, Ka SM, Chang JM et al. Epigallocatechin-3-gallate prevents lupus nephritis development in mice via enhancing the Nrf2 antioxidant pathway and inhibiting NLRP3 inflammasome activation. Free Radic Biol Med 2011; 51: 744-754
29. Okamoto T. NF-kappaB and rheumatic diseases. Endocr Metab Immune Disord Drug Targets 2006; 6: 359-372
30. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci 2004; 75: 639-653
31. Wang G, Pierangeli SS, Papalardo E et al. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: Correlation with disease activity. Arthritis Rheum 2010; 62: 2064-2072
32. Wakabayashi N, Slocum SL, Skoko JJ et al. When NRF2 talks who's listening? Antioxid Redox Signal 2010; 13: 1649-1663
33. Liu YC, Hsieh CW, Wu CC et al. Chalcone inhibits the activation of NFkappaB and STAT3 in endothelial cells via endogenous electrophile. Life Sci 2007; 80: 1420-1430
34. Yang H, Magilnick N, Lee C et al. Nrf1 and Nrf2 regulate rat glutamatecysteine ligase catalytic subunit transcription indirectly via NF-kappaB and AP-1. Mol Cell Biol 2005; 25: 5933-5946
35. Chen XL, Dodd G, Thomas S et al. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am J Physiol Heart Circ Physiol 2006; 290: H1862-H1870
36. Qing X, Zavadil J, Crosby MB et al. Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells. Arthritis Rheum 2006; 54: 2198-2210
37. Katz JB, Limpanasithikul W, Diamond B. Mutational analysis of an autoantibody: Differential binding and pathogenicity. J Exp Med 1994; 180: 925-932